

复正常,不影响下一周期的化疗,多西他赛和培美曲塞给药前均给予充分预处理,未见到1例过敏反应。

综上所述,DP方案和PP方案一线治疗晚期肺腺癌疗效确切,且两组方案近期疗效相近,不良反应可耐受,均可作为治疗晚期肺腺癌的有效选择,但是需要依据患者的个体情况调整药物剂量及治疗方案。例如,老年患者、体弱者需要适当减量;经济条件一般者可选用DP方案等,避免给患者带来身体上的痛苦和经济上的额外负担,使姑息化疗既能体现治疗的个体化又有临床疗效。

#### 参考文献

- [1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015 [J]. *CA Cancer Clin*, 2015, 67(1): 5-29.
- [2] 孙燕. 抗肿瘤药物的近期和远期不良反应[M]//孙燕,石远凯. 临床肿瘤内科手册. 5版. 北京:人民卫生出版社,2007:142-145.
- [3] Rothschild SI. Targeted therapies in non-small cell lung cancer-beyond EGFR and ALK [J]. *Cancers (Basel)*, 2015, 7(2): 930-949.
- [4] 石远凯,孙燕. 中国非小细胞肺癌分子靶向治疗十年[J]. *中华医学杂志*, 2015, 95(8): 564-569.
- [5] Aggarwal C. Targeted therapy for lung cancer: present and future [J]. *Ann Palliat Med*, 2014, 3(3): 229-235.
- [6] Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M [J]. *Nat Med*, 2015, 21(6): 560-562.
- [7] Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small cell lung cancer [J]. *N Engl J Med*, 2015, 372(18): 1689-1699.
- [8] Jiang T, Zhou C. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer [J]. *Transl Lung Cancer Res*, 2014, 3(6): 370-372.
- [9] Teixidó C, Karachaliou N, González-Cao M, et al. Assays for predicting and monitoring responses to lung cancer immunotherapy [J]. *Cancer Biol Med*, 2015, 12(2): 87-95.
- [10] Shan J, Xiong Y, Wang D, et al. Nedaplatin-versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer [J]. *Mol Clin Oncol*, 2015, 3(3): 543-549.
- [11] Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial [J]. *Lancet Oncol*, 2015, 16(7): 763-774.
- [12] 刘爱学,李明淑,周泽,等. 多西他赛与吉西他滨分别联合顺铂治疗晚期非小细胞肺癌的临床疗效观察[J]. *海南医学*, 2013, 24(2): 171-173.
- [13] 林立平,胡家柱,黄福,等. 吉西他滨联合化疗与其他方案治疗晚期非小细胞肺癌233例疗效比较[J]. *海南医学*, 2014, 25(1): 18-21.
- [14] Chen B, Zheng J, Zeng Y, et al. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism [J]. *PLoS One*, 2014, 9(12): e114074.
- [15] Reck M, Kaiser R, Mellemaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial [J]. *Lancet Oncol*, 2014, 15(2): 143-155.
- [16] Khodadad K, Khosravi A, Esfahani-Monfared Z, et al. Comparing docetaxel plus cisplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: a single institute study [J]. *Iran J Pharm Res*, 2014, 13(2): 575-581.
- [17] Kubota K, Sakai H, Katakami N, et al. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small cell lung cancer: TCOG0701 CATS trial [J]. *Ann Oncol*, 2015, 26(7): 1401-1408.
- [18] Barlesi F, Chouaid C, Crequit J, et al. A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective [J]. *Interact Cardiovasc Thorac Surg*, 2015, 20(6): 783-790.
- [19] Yoshimura N, Kudoh S, Mitsuoka S, et al. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation [J]. *Lung Cancer*, 2015, 90(1): 65-70.
- [20] Zhong A, Xiong X, Shi M, et al. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis [J]. *Drug Des Devel Ther*, 2015, 20(9): 3685-3693.
- [21] Liu ZF, Wei ZM, Hu Y, et al. A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage III B/IV non-small-cell lung cancer [J]. *Med Oncol*, 2015, 32(8): 660-665.

(收稿日期:2015-10-15)